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Abstract: Objectives: This paper aims to describe the clinical experience with Daratumumab (DARA),
a first-in-class anti-CD38 human monoclonal IgG1κ antibody monotherapy, in severe patients with
AL and biopsy-proven renal involvement. Immunoglobulin light chain (AL) amyloidosis with
multi-organ involvement is characterized by short survival. Novel powerful drugs are expanding
the therapeutic options. Current treatment of AL amyloidosis, which has been adopted from
multiple myeloma (MM), is based on chemotherapy targeting the underlying plasma cell clone.
DARA is effective in treating MM. The clinical activity and toxicity profile of DARA as a single
agent in the treatment of AL amyloidosis is currently under evaluation. Patients and Methods:
DARA was administered in a series of patients with severe AL amyloidosis and biopsy-proven
renal involvement. Five patients(mean age 64.2 years) were treated. One patient was refractory
and one intolerant to conventional bortezomib-based therapy, two were treated with DARA for
relapsing disease, and one was treated front-line. Results: Data showed that DARA monotherapy
resulted in good clinical results, with the disappearance of M-proteins in four out of five patients
and with serum free light chains (sFLC) ratio normalization in three out of four and a remarkable
amelioration in the remaining patient. The four patients with still preserved renal function at
baseline also showed serum creatinine stabilization or improvement and a decrease in proteinuria.
These data were paralleled by the reduction of the N-terminal prohormone of brain natriuretic
peptide (NT pro-BNP)values. Conclusions: Our data show that monotherapy with DARA had
significant clinical efficacy in pretreated/naïve patients with severe AL amyloidosis and biopsy-proven
renal involvement.
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1. Introduction
Immunoglobulin light chain (AL) amyloidosis with multi-organ involvement is characterized by
short survival. Outcomes are especially poor for patients who have cardiac and/or renal involvement.
In recent years, our understanding of the pathogenesis of AL amyloidosis and the mechanisms of organ
involvement has greatly improved, and a good deal of progress has been made in biomarker-based
risk stratification and disease monitoring. As a consequence, novel powerful drugs are expanding
the therapeutic options [1]. Overall, these advances are resulting in improved outcomes [2]. Traditional
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treatment of AL amyloidosis includes the use of stem cell transplantation in a minority of patients,
while the majority are treated with proteasome inhibitors, alkylating agents, and/or steroid-based
combinations [3]. Indeed, current treatment of AL amyloidosis has been derived from multiple
myeloma (MM), and is based on chemotherapy targeting the underlying plasma cell clone. Achieving
the disappearance (i.e., complete hematological response) or at least a reduction in the involved free
light chains (FLC) is considered a critical endpoint which is thought to be crucial for preventing further
organ damage [4].
Daratumumab (DARA)is a first-in-class anti-CD38 human IgG1κ monoclonal antibody (MoAb)
that is effective in treating relapsed/refractory multiple myeloma both as monotherapy and in
combination with proteasome inhibitors and immunomodulatory drugs [5,6].The clonal plasma cells
in AL amyloidosis express CD38, thus making DARA a potentially effective treatment [7]. Early data
from phase I and phase II studies show that DARA is well tolerated in this population of patients
and that it induces rapid and in-depth response. The clinical activity and toxicity profile of DARA as
a single agent in the treatment of AL amyloidosis is currently under evaluation (NCT04131309). We
describe a specific experience with DARA monotherapy in a series of patients with severe AL and
biopsy-proven renal involvement.
2. Patient Cohort
Five patients (two males and three females), mean age 64.2 years (range 52–69), affected by AL
amyloidosis with biopsy-proven renal involvement, were treated with DARA following antibody
testing and extended red blood cell (RBC) antigen phenotyping. The treatment protocol included
16 mg/kg DARA administered intravenously weekly for 8 consecutive weeks, then every two weeks
eight more times, and lastly monthly until the 52nd week. Premedication included paracetamol
1000 mg (oral), chlorphenamine 10 mg (intravenous), methylprednisolone 125 mg (intravenous).
Demographics, clinical features, and response to therapy are reported in Tables 1 and 2. Table 3
includes histological information from kidney biopsy.
Case 1 (a bortezomib-based regimen resistant case). The patients had a history of hypertension
and presented with nephrotic syndrome to our division. Assessment of M component showed IgAλ,
with FLC λ 670 mg/L, FLC ratio 0.02. Renal biopsy confirmed AL amyloidosis, and bone marrow
showed a λ-restricted plasma cell clone (7%) positive with Congo red staining. Clinical, laboratory, and
radiological tests revealed class I cardiac failure according to the New York Heart Association (NYHA)
classification and a peripheral nervous system involvement. The patient was treated with five courses
of bortezomib (1.3 mg/m2), cyclophosphamide (1000 mg/m2), and dexamethasone (160 mg/week)
(VCD), without response. He was subsequently treated with four courses of melphalan (10 mg/day) and
dexamethasone (20 mg/day) for 4 days/month, but further progressed with an estimated glomerular
filtration rate (eGFR) dropping from 70 to 15 mL/min/1.73 m2, unchanged proteinuria (12 g/24 h),
and an increase in N-terminal prohormone of brain natriuretic peptide (NT pro-BNP)from 593 to
8296 pg/mL.
He underwent a second renal biopsy which showed an increase in amyloid deposits and a bone
marrow biopsy which revealed an unchanged percentage of plasma cells. Treatment with DARA
resulted in a decrease in NT pro-BNP levels (from 8296 to 4526 pg/mL), disappearance of serum
M-component, and Bence–Jones proteinuria and normalization of FLC ratio. However, because of
a persistently impaired renal function with eGFR of 7 mL/min/1.73 m2, hemodialysis was started. No
infusion-related reactions or adverse events were observed with DARA. Treatment was discontinued
at the 52nd week and a third renal biopsy was performed. The amyloid deposits were unchanged, but
there was a significant increase in sclerotic glomeruli and interstitial fibrosis. The patient is currently
being evaluated for kidney transplantation.
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Pt 1 68 IgAλ 7% II + B-CYC-DM-D 0.02 16.8 8296 ++ HD −−
Pt 2 55 λ 8% I ++ M-D 0.22 1.9 1844 ++ 0.7 6.8
Pt 3 70 λ 9% I − −− 0.06 3.79 850 ++ 2.3 9.3
Pt 4 67 IgDλ 13% −− −− B-CYC-D(1 cycle) 0.12 4.53 175 ++ 0.4 8.2
Pt 5 72 IgGλ 7% −− −− L-CYC-D 0.21 2.3 328 ++ 0.8 2.5
B: bortezomib, CYC: cyclophosphamide, D: dexamethasone, M: melphalan, L: lenalidomide, FLC: free light chain, sCr: creatinine, uPT: proteinuria, BM, bone marrow, NYHA, New York
Heart Association.-terminal prohormone of brain natriuretic peptide (NT pro-BNP).
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dose A I 0.49 9048 −− −− −− 0
End FU A I 0.53 4526 −− −− −− 0
Pt 2
13th
dose A I 1.06 337 Neg 0.7 2.8 0
End FU A I 1.05 330 Neg 0.8 2.7 0
Pt 3
13th
dose R I 0.1 213 +/− 1.7 2.3 0
End FU A I 0.25 225 Neg 1.5 2.2 0
Pt 4 *
13th




dose R −− 0.29 369 + 0.7 1 0
End FU
FLC: free light chain, sCr: creatinine, uPT: proteinuria, A:absent, R: reduced, FU: follow-up. * For pt 4 and pt 5, the 13th dose match.
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Pt 1 38/38 + ++ Lambda +++
Pt 2 31/34 + ++ Lambda: +++
Pt 3 17/17 +++ ++ Lambda: +++
Pt 4 14/18 ++ +++ Lambda: +++
Pt 5 18/24 + +/− Lambda +++
IF, immunofluorescence.
Case 2 (a relapsing case). The patient presented with anemia (hemoglobin 10.7 g/dL), nephrotic
syndrome (proteinuria 4.5 g/24 h), asthenia, and paresthesia of the lower limbs. Assessment of M
component was positive for light chain λ. Renal biopsy showed AL amyloidosis, and bone marrow
analysis revealed a λ-restricted plasma cell clone (8%). Clinical, laboratory, and radiological tests
indicated cardiac and peripheral nervous system involvement. The patient was treated with nine
courses of melphalan i.v. and dexamethasone (20 mg/day) for 4 days/month, which resulted in
a complete response. Two years later, the FLC ratio decreased to 0.22, with FLC λ 73.5 mg/L, and
proteinuria increased from 1.2 to 6.8 g/24 h with reappearance of Bence–Jones proteinuria. This was
paralleled by a relapse of lower limb paresthesia. Renal biopsy confirmed an increase in amyloid
deposits, electromyography revealed a severe peripheral neuropathy, and bone marrow analysis
showed a λ-restricted plasma cell clone 7%. Treatment with DARA resulted in a rapid decrease in
proteinuria (from 6.8 to 2.7 g/24 h at the 16th dose) and NT pro-BNP levels (from 1844 to 330 pg/mL) with
disappearance of serum M component and Bence–Jones proteinuria and normalization of FLC ratio.
Again, no infusion-related reactions or adverse events were observed. Treatment is currently ongoing.
Case 3 (a front-line administration case). The patient had a previous a history of intestinal
diverticulosis (for which he underwent surgical resection in 2008) and presented with nephrotic
syndrome (proteinuria 9.3 g/24 h), Bence–Jones proteinuria, and renal failure (sCr 2.4 mg/dL).
Assessment of M component was positive for light chain λ with FLC λ 390 mg/L and FLC ratio
0.06. Renal biopsy showed AL amyloidosis, and bone marrow analysis revealed a λ-restricted plasma
cell clone (9% of infiltration). Clinical, laboratory, and radiological tests indicated class I NYHA-,
New York Heart Association cardiac failure. Treatment with DARA resulted in a rapid decrease in
proteinuria (from 9.3 to 2.2 g/24 h at the 16th dose) with weakly positive Bence–Jones proteinuria,
normalization of FLC ratio and disappearance of serum M component, and reduction in NT pro-BNP
levels from 850 to 225 pg/mL. No infusion-related reactions or adverse events were noted. Treatment is
currently ongoing.
Case 4 (a bortezomib-based regimen intolerant case).The patient had a history of severe
malabsorption syndrome, for which parenteral nutrition was started two years before. The patient
presented with cachexia and depressive syndrome. Laboratory tests revealed nephrotic syndrome
(proteinuria 8.2 g/24 h), Bence–Jones proteinuria associated with marked hypoprotidemia (serum
albumin 1.2 g/dL and total serum proteins of 3.5 g/dL). She had an IgDλ M component with FLC
λ 134 mg/L and FLC ratio 0.12. Tissue histological examination confirmed the clinical suspicion of
amyloid deposits in the kidney, intestinal mucosa, and periombelical fat. Bone marrow showed
a λ-restricted plasma cell clone (13%), and testing with Congo red staining was positive. No signs
of cardiac or peripheral nervous system involvement were found. The patient was initially treated
with bortezomib (1.3 mg/m2), cyclophosphamide (1000 mg/m2), and dexamethasone (160 mg/week),
but the protocol was discontinued after the first cycle because of intolerance and the appearance
of leukocytopenia. Treatment with DARA resulted in a rapid decrease in proteinuria (from 8.2 to
1.9 g/24 h at the 13th dose) with disappearance of Bence–Jones proteinuria and serum M component
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and normalization of FLC ratio. No infusion related reactions were observed. After the 13thinfusion,
the patient was hospitalized for pneumonia and treatment was temporarily discontinued.
Case 5 (a relapsing case). The patient had a history of hypothyroidism and presented with nephrotic
syndrome (proteinuria 4.7 g/24 h). Assessment of M component was positive for IgGλ. Renal biopsy
showed AL amyloidosis, and bone marrow analysis revealed a λ-restricted plasma cell clone (12%).
Clinical and electrophysiologic tests indicated peripheral nervous system involvement, while cardiac
involvement was excluded. The patient was treated with nine courses of Lenalidomide (15 mg/day,
day 1–21), cyclophosphamide (300 mg/m2, days 1-8-15), and dexamethasone (160 mg/month), which
resulted in a complete response. Six years later, the FLC ratio decreased to 0.21, FLC λ was 73.5 mg/L
and total proteinuria and Bence Jones proteinuria reappeared (2.5 g/24 h). Renal biopsy showed
amyloid deposits. Bone marrow analysis revealed a λ-restricted plasma cell clone (7%). No cardiac
or peripheral nervous system involvement was detected. Treatment with DARA resulted in a rapid
decrease in proteinuria (from 2.5 to 1 g/24 h at the 13th dose) and serum M component and an increase in
FLC ratio (0.29, nv: 0.31–1.56), with weakly positive Bence–Jones proteinuria. The patient experienced
an infusion reaction during the first dose (grade 1). No other adverse events were noted. Treatment is
currently ongoing.
3. Discussion
AL amyloidosis is a rare disease caused by clonally restricted plasma cells that produce monoclonal
light chains which form insoluble fibrils that are then deposited into vital organs including the heart in
60% of cases, and the kidney in 70%, thus inducing irreversible cell damage [8].
Survival of patients with AL amyloidosis is widely heterogeneous and depends on the degree
of organ involvement. Advanced cardiac involvement is associated with the worst outcome [2].
Kidney involvement is not directly associated with reduced survival but does influence both access to
innovative therapy and quality of life [9].
Prognostic classifications include the standard Mayo Staging System (MSS) (which considers
cardiac troponins and NT pro-BNP [10]), the 2014 revised MSS version (that incorporates the level
of pathologic light chain [11]), and a more recently proposed Staging System using BNP detection
(which is more commonly available than NT pro-BNP and is less influenced by renal impairment [12]).
A staging system based on glomerular filtration rate (GFR) and proteinuria at diagnosis has been
found to predict the risk of progression to end-stage kidney disease in a large cohort of patients with
a presumptive diagnosis of kidney amyloidosis (mostly based on clinical grounds) [7]. However,
whether this staging system can be applied to patients with biopsy-proven renal involvement is
presently speculative.
The goals of therapy in AL amyloidosis is a suppression of the production of the pathologic light
chain precursor in order to improve organ impairment. This is difficult to achieve because the process
of amyloid deposition, at least in the kidney, is hardly reversible [13]. Indeed, repeat biopsies show
the persistence of deposits even in patients with renal response. When treated with bortezomib-based
regimens, patients with renal involvement show a complete hematologic response in half of the cases.
Hematologic response is an essential prerequisite for maintaining or improving renal function. Indeed,
a >90% response in free light chains at 6 months has been associated with a four-fold increase in
the likelihood of renal response [14]. A delay in hematologic response results in further deposition of
amyloid that reduces the chances of renal improvement. This is why a more aggressive treatment than
the conventional bortezomib-based regimen is desirable ab initio in these high-risk patients.
DARA is a highly effective anti-plasma cell therapy that has become integral in the treatment of
multiple myeloma. It has rapidly shifted from being an agent to be used in relapsed/refractory settings
to a drug with a putative role in the early disease course. Clinical trials are currently investigating its
efficacy in the front-line setting [15].
Previous studies have shown encouraging data regarding the safety, tolerability, and effectiveness
(with a hematologic response rate >80) of daratumumab-based therapies in AL amyloidosis [16–19].
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Renal response has not been specifically addressed in these studies.
In a phase II study, Sanchorawala et al. also reported high hematologic response rates (>80%) in
21 patients with relapsed AL amyloidosis [20].
In another cohort, 84 patients with previously treated AL amyloidosis who received DARA (with
dexamethasone alone or in combination with other plasma-cell directed therapies) were retrospectively
evaluated for survival and organ response. Sixty-seven (84%) out of 80 evaluable patients achieved
a hematologic response. Sixty-eight patients (81%) had cardiac involvement, and 53% of evaluable
patients achieved a cardiac response with a median initial response time of 2 months among responders.
Of the 53 patients with renal impairment or urinary abnormalities, 26 were evaluable and achieved some
renal response, with a median initial response time of 6 months [21]. However, none of the patients in
these series were reported as having biopsy-proven renal involvement.
The presence of amyloids unique proof of kidney involvement. Due to the several causes of
proteinuria in the elderly, renal biopsy should be performed in all cases of urinary abnormalities
despite the finding of positive Congo red staining in another tissue. The extent and distribution of
renal amyloid deposition might also be important when comparing the outcomes of these patients [22].
The results of a prospective multicenter phase II study of DARA monotherapy in AL amyloidosis
have been very recently published [23].Forty previously treated patients from 15 centers were examined.
They included 26 patients with renal involvement. They had no renal biopsy and no insight into
the definition of renal involvement had been given. Twenty-one of them had <60 mL/mi of eGFR. This
figure, considering patients’ mean age (69 years), is close to normal. Seven patients were claimed to
have a renal response because of a 30% decrease in proteinuria without a 25% increase in eGFR, but no
detail of the baseline proteinuria levels had been given.
Taken together, these results are difficult to interpret.
When compared to the available evidence, while confirmation in a larger study is needed,
nevertheless, the marked decrease in proteinuria and Bence–Jones protein, along with the disappearance
of the M component, represent a major point of interest in our study.
4. Conclusions
The present study describes five patients with AL amyloidosis and biopsy-proven renal
involvement who underwent DARA monotherapy in a single center. Our data, based on real
life experience and strong parameters of definition of the renal involvement, showed this regimen to
be a beneficial therapeutic option capable not only of inducing rapid hematologic response but also
achieving a substantial rate of renal improvement in pretreated and naïve patients.
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